StageZero provides advanced diagnostics that can not only identify cancer earlier among employees, but also identify the early warning signs that can lead to a future cancer diagnosis. This paired with a physician supervised intervention program run by experienced oncologists can reduce costs for your organization dramatically.

The Following Case-Study Demonstrates a 58% Reduction in Breast Cancer Costs Alone through Early Interventions

Presumptions

• In a target population of 1,000 women 12.9% will develop Breast Cancer in their lifetime(1)
• With a 65% average compliance rate with breast cancer in the U.S. (2)​, you can expect to find 84 Cancers
• If only 84 employees have been screened, how do you address the 45 employees who have cancer, but have not been diagnosed?

Predicted Financial Benefit

• According to a 2022 study by BMC Health Services Research, the average cost of treating Stage 1 Breast cancer is $56,507; whereas the cost of treating a Stage-4 Breast Cancer is $133,100 (3)
• The late-stage cost of treating 45 employees with late-stage Breast Cancer is $5,989,500
• If caught early in the same 45 employees, the cost would only be $2,542,815

​A Cost Avoidance of $3,446,685
For Breast Cancer Alone

Our Programs Enhance Your Benefits 

ARISTOTLE®
Addressing Today's Cancer Earlier

Did you know 50% of Cancers are still found in the late stages when outcomes are poor and costs are high?

Aristotle® is a new blood test that can detect the molecular signatures of multiple cancers from a single sample of blood to help you find cancer earlier and start treatment when it can dramatically improve patient outcomes.Aristotle can discretely detect each cancer signature with high sensitivity and specificity. (4) Today Aristotle can detect 9 specific cancers: 
Ovarian, Breast, Endometrial, Cervical, Bladder, Prostate, Colorectal, 
Liver and Stomach. 

​Our underlying mRNA technology, The Sentinel Principle, has been validated in more than ​9,000 patients and used by more than 100,000 patients in North America. (4) 

Learn More

​AVRT™
Addressing Tomorrow's Cancer Today

Did you know 40% of the most common cancers are preventable through modifiable risk factors(5)?

AVRT (pronounced "avert") identifies early risk factors that may lead to cancer and provides actionable information to help people adopt lifestyle modifications to help reduce their risk. ​

​We assess the inflammatory and metabolic pathways that have been demonstrated to increase the risk of developing cancer and other chronic diseases.

Learn More

The Current Cancer Crisis

• ​​Approximately 1.9 Million Americans and 200,000 Canadians will be diagnosed with Cancer this year(6,7). 
• 50% of cancers are still diagnosed in the later stages when outcomes are poor and costs are high (8). 
• 40% of these cancers are preventable through risk modification programs (5)​
• Cancer is now the #1 catastrophic claim for self-funded health plans​​

---

Contact us today

Why You Need to Act Now!

​​​​​The cost of doing nothing for early cancer detection and prevention is sizable: 

• ​loss of life
• loss of productivity
• longer disability durations
• millions of dollars in biologic drugs/healthcare expenses for patients, employers, health systems and insurers. ​

​

Early Means Everything

The average cost of late-stage cancer diagnosis is almost 2-3 times the cost of an early-stage diagnosis (3). Finding cancer earlier reduces costs.

Survival rates dramatically improve when cancer is found in the early stages. (8)

References
1. https://www.cancer.gov/types/breast/risk-fact-sheet 
2.https://www.cdc.gov/nchs/hus/topics/mammography.html
3. McGarvey, N., Gitlin, M., Fadli, E. et al. Increased healthcare costs by later stage cancer diagnosis. BMC Health Serv Res 22, 1155 (2022). https://doi.org/10.1186/s12913-022-08457-6American
4. Aristotle: A single blood test for pan-cancer screening. Dempsey AA, Chao S, Stamatiou D, Pilcz T, Ying J, Burakoff R. Journal of Clinical Oncology 2020; 38:15_suppl e15037
5. GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022 Aug 20;400(10352):563-591. doi: 10.1016/S0140-6736(22)01438-6. PMID: 35988567. 
6. Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022. (Accessed 1.30.22)
7. Canadian Cancer Statistics Advisory Committee in collaboration with the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada. Canadian Cancer Statistics 
8. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33. 
​9. 2022 Sun Life Stop-Loss Research Report: High-cost Claims and Injectable Drug Trends Analysis.